Sage Therapeutics Inc. (NASDAQ:SAGE) shares were up 3.4% during mid-day trading on Friday . The stock traded as high as $44.97 and last traded at $44.86, with a volume of 208,487 shares. The stock had previously closed at $43.39.

Several research analysts recently issued reports on SAGE shares. Leerink Swann reissued a “buy” rating on shares of Sage Therapeutics in a report on Monday, May 16th. Canaccord Genuity reissued a “buy” rating on shares of Sage Therapeutics in a report on Wednesday, June 8th. Cowen and Company reissued a “buy” rating on shares of Sage Therapeutics in a report on Wednesday, June 8th. Zacks Investment Research cut shares of Sage Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 12th. Finally, Goldman Sachs Group Inc. reissued a “buy” rating and set a $63.00 price target on shares of Sage Therapeutics in a report on Friday, April 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $66.18.

The firm’s market capitalization is $1.42 billion. The firm has a 50-day moving average price of $33.59 and a 200 day moving average price of $34.67.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.97) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.98) by $0.01. Equities analysts predict that Sage Therapeutics Inc. will post ($4.34) earnings per share for the current year.

In other news, Director Kevin P. Starr sold 850,000 shares of the business’s stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $31.25, for a total transaction of $26,562,500.00. Following the sale, the director now owns 65,227 shares in the company, valued at $2,038,343.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Kimi Iguchi sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 12th. The shares were sold at an average price of $49.55, for a total transaction of $247,750.00. Following the sale, the chief financial officer now owns 83,739 shares in the company, valued at approximately $4,149,267.45. The disclosure for this sale can be found here.

Other hedge funds and institutional investors recently added to or reduced their stakes in the company. Jennison Associates LLC bought a new position in Sage Therapeutics during the fourth quarter valued at $14,875,000. Marshall Wace LLP bought a new position in Sage Therapeutics during the fourth quarter valued at $1,870,000. BB Biotech AG bought a new position in Sage Therapeutics during the fourth quarter valued at $41,315,000. GAM Holding AG raised its position in Sage Therapeutics by 74.1% in the fourth quarter. GAM Holding AG now owns 79,400 shares of the biopharmaceutical company’s stock valued at $4,629,000 after buying an additional 33,800 shares in the last quarter. Finally, ProShare Advisors LLC raised its position in Sage Therapeutics by 8.2% in the fourth quarter. ProShare Advisors LLC now owns 25,219 shares of the biopharmaceutical company’s stock valued at $1,470,000 after buying an additional 1,919 shares in the last quarter.

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening, rare central nervous system (CNS) disorders. The Company’s lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.